Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy

Annals of the New York Academy of Sciences

Volumn 1284, Issue 1, 2013, Pages 80-86

  Kawakami, Yutaka ^a   Yaguchi, Tomonori ^a   Sumimoto, Hidetoshi ^a   Kudo Saito, Chie ^a   Tsukamoto, Nobuo ^a   Iwata Kajihara, Tomoko ^a   Nakamura, Shoko ^a   Nishio, Hiroshi ^a   Satomi, Ryosuke ^a   Kobayashi, Asuka ^a   Tanaka, Mayuri ^a   Park, Jeong Hoon ^a   Kamijuku, Hajime ^a   Tsujikawa, Takahiro ^a   Kawamura, Naoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BRAF; Immunosuppression; NF B; STAT3; catenin

Indexed keywords

B RAF KINASE INHIBITOR; BETA CATENIN; CANCER VACCINE; CHEMOKINE; CYTOKINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE INHIBITOR; KAMPO; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; SUNITINIB; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MELANOMA CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

EID: 84877331674     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12094     Document Type: Article

References (28)

1. Kawakami, Y., T. Fujita, Y. Matsuzaki, et al. 2004. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci. 95: 784-791.
2. Kawakami, Y., S. Eliyahu, C.H. Delgado, et al. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 91: 3515-1519.
3. Kawakami, Y., S. Eliyahu, C.H. Delgado, et al. 1994. Identification of human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 91: 6458-6462.
4. Kawakami, Y., S. Eliyafu & C. Jennings 1995. Recognition of multiple epitopes in the human melanoma antigens gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J. Immunol. 154: 3961-3968.
5. Parkhurst, M.R., M.L. Salgaller, S. Southwood, et al. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J. Immunol. 157: 2539-2548.
6. Rosenberg, S.A., J. Yang, D. Schwartzentruber, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
7. Schwartzentruber, D.J., D.H. Lawson, J.M. Richards, et al. 2011. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364: 2119-2127.
8. Rosenberg, S.A., J.C. Yang, R.M. Sherry, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
9. Schreiber, R.D., L.J. Old & M.J. Smyth 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
10. Yaguchi, T., H. Sumimoto, C. Kudo-Saito, et al. 2011. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 93: 294-300.
11. Fridman, W.H., F. Pagès, C. Sautès-Fridman & J. Galon 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12: 298-306.
12. Galon, J., F. Pagès, F.M. Marincola, et al. 2012. Cancer classification using the immunoscore: a worldwide task force. J. Transl. Med. 10: 205.
13. Fuertes, M.B., S.R. Woo, B. Burnett, et al. 2013. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34: 67-73.
14. Tsujikawa, T., T. Yaguchi, G. Ohmura, et al. 2013. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma. Int. J. Cancer. DOI: 10.1002/ijc.27966.
15. Kudo-Saito, C., H. Shirako, T. Takeuchi & Y. Kawakami 2009. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195-206.
16. Sumimoto, H., M. Miyagishi, H. Miyoshi, et al. 2004. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031-6039.
17. Sumimoto, H., F. Imabayashi, T. Iwata & Y. Kawakami 2006. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203: 1651-1656.
18. Chapman, P.B., A. Hauschild, C. Robert, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364: 2507-2516.
19. Boni, A., A.P. Cogdill, P. Dang, et al. 2010. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70: 5213-5219.
20. Wilmott, J.S., G.V. Long, J.R. Howle, et al. 2011. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18: 1386-1394.
21. Iwata-Kajihara, T., H. Sumimoto, N. Kawamura, et al. 2011. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J. Immunol. 187: 27-36.
22. Kortylewski, M., M. Kujawski, T. Wang, et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11: 1314-1321.
23. Lee, H., S.K. Pal, K. Reckamp, et al. 2011. STAT3: a target to enhance antitumor immune response. Curr. Top. Microbiol. Immunol. 344: 41-59.
24. Burdelya, L., R. Catlett-Falcone, A. Levitzki, et al. 2002. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol. Cancer Ther. 1: 893-899.
25. Ko, J.S., A.H. Zea, B.I. Rini, et al. 2009. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15: 2148-2157.
26. Mustjoki, S., M. Ekblom, T.P. Arstila, et al. 2009. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23: 1398-405.
27. Tsukamoto, N., S. Okada, Y. Onami, et al. 2009. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin. Cancer Res. 15: 5733-5743.
28. Yaguchi, T., Y. Goto, K. Kido, et al. 2012. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J. Immunol. 189: 2110-2117.